Does the media favor SVRA or AKBA?

In the previous week, Akebia Therapeutics had 8 more articles in the media than Savara. MarketBeat recorded 9 mentions for Akebia Therapeutics and 1 mentions for Savara. Akebia Therapeutics' average media sentiment score of 0.27 beat Savara's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AKBA or CALT?

Akebia Therapeutics presently has a consensus price target of $4.67, suggesting a potential upside of 276.34%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Akebia Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Akebia Therapeutics (AKBA) Competitors

$1.24 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.22 -0.02 (-1.53%)

As of 07/2/2026 07:47 PM Eastern

Compare

AKBA vs. SVRA, CALT, COLL, CRVS, and CGEM

Should you buy Akebia Therapeutics stock or one of its competitors? MarketBeat compares Akebia Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akebia Therapeutics include Savara (SVRA), Calliditas Therapeutics AB (publ) (CALT), Collegium Pharmaceutical (COLL), Corvus Pharmaceuticals (CRVS), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.

How does Akebia Therapeutics compare to Savara?

Savara (NASDAQ:SVRA) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

Savara has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Akebia Therapeutics' return on equity of -62.72% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

87.9% of Savara shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Savara currently has a consensus price target of $10.14, suggesting a potential upside of 63.07%. Akebia Therapeutics has a consensus price target of $4.67, suggesting a potential upside of 276.34%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Akebia Therapeutics had 8 more articles in the media than Savara. MarketBeat recorded 9 mentions for Akebia Therapeutics and 1 mentions for Savara. Akebia Therapeutics' average media sentiment score of 0.27 beat Savara's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akebia Therapeutics has higher revenue and earnings than Savara. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Akebia Therapeutics	$236.20M	1.41	-$5.34M	-$0.08	N/A

Savara has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Summary

Savara and Akebia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Calliditas Therapeutics AB (publ)?

Akebia Therapeutics (NASDAQ:AKBA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Akebia Therapeutics had 9 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 9 mentions for Akebia Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Akebia Therapeutics' average media sentiment score of 0.27 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Akebia Therapeutics	Neutral
Calliditas Therapeutics AB (publ)	Neutral

Akebia Therapeutics has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.41	-$5.34M	-$0.08	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Akebia Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Akebia Therapeutics has a net margin of -8.83% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Akebia Therapeutics' return on equity of -62.72% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Akebia Therapeutics presently has a consensus price target of $4.67, suggesting a potential upside of 276.34%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Akebia Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Akebia Therapeutics beats Calliditas Therapeutics AB (publ) on 14 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$796.33M	1.51	$62.87M	$2.04	18.15
Akebia Therapeutics	$236.20M	1.41	-$5.34M	-$0.08	N/A

In the previous week, Akebia Therapeutics had 8 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 9 mentions for Akebia Therapeutics and 1 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 1.50 beat Akebia Therapeutics' score of 0.27 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
Collegium Pharmaceutical	Very Positive
Akebia Therapeutics	Neutral

33.9% of Akebia Therapeutics shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Collegium Pharmaceutical has a net margin of 9.41% compared to Akebia Therapeutics' net margin of -8.83%. Collegium Pharmaceutical's return on equity of 95.18% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Collegium Pharmaceutical presently has a consensus target price of $57.50, indicating a potential upside of 55.28%. Akebia Therapeutics has a consensus target price of $4.67, indicating a potential upside of 276.34%. Given Akebia Therapeutics' higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Collegium Pharmaceutical beats Akebia Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Corvus Pharmaceuticals presently has a consensus target price of $33.33, indicating a potential upside of 118.87%. Akebia Therapeutics has a consensus target price of $4.67, indicating a potential upside of 276.34%. Given Akebia Therapeutics' higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Corvus Pharmaceuticals has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Corvus Pharmaceuticals' return on equity of -38.92% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Akebia Therapeutics has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Akebia Therapeutics	$236.20M	1.41	-$5.34M	-$0.08	N/A

Corvus Pharmaceuticals has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

In the previous week, Akebia Therapeutics had 9 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 9 mentions for Akebia Therapeutics and 0 mentions for Corvus Pharmaceuticals. Akebia Therapeutics' average media sentiment score of 0.27 beat Corvus Pharmaceuticals' score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Corvus Pharmaceuticals	Neutral
Akebia Therapeutics	Neutral

Summary

Akebia Therapeutics beats Corvus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Akebia Therapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Akebia Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Akebia Therapeutics	$236.20M	1.41	-$5.34M	-$0.08	N/A

Cullinan Therapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cullinan Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Cullinan Therapeutics' return on equity of -51.45% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

In the previous week, Akebia Therapeutics had 9 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 9 mentions for Akebia Therapeutics and 0 mentions for Cullinan Therapeutics. Akebia Therapeutics' average media sentiment score of 0.27 beat Cullinan Therapeutics' score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cullinan Therapeutics	Neutral
Akebia Therapeutics	Neutral

Cullinan Therapeutics presently has a consensus price target of $32.00, suggesting a potential upside of 81.51%. Akebia Therapeutics has a consensus price target of $4.67, suggesting a potential upside of 276.34%. Given Akebia Therapeutics' higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Akebia Therapeutics beats Cullinan Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKBA vs. The Competition

Export

Metric	Akebia Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$332.64M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-15.50	20.06	28.02	24.70
Price / Sales	1.41	360.33	540.37	99.46
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	10.33	4.32	10.96	6.46
Net Income	-$5.34M	$64.45M	$3.57B	$337.01M
7 Day Performance	8.77%	2.97%	2.12%	1.69%
1 Month Performance	32.58%	6.83%	5.25%	3.81%
1 Year Performance	-65.60%	29.07%	33.29%	23.90%

Akebia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKBA Akebia Therapeutics	2.357 of 5 stars	$1.24 flat	$4.67 +276.3%	-65.6%	$332.64M	$236.20M	N/A	430	News Coverage Analyst Forecast Gap Up
SVRA Savara	1.7115 of 5 stars	$6.03 +2.2%	$10.14 +68.2%	+191.3%	$1.21B	N/A	N/A	20	News Coverage
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
COLL Collegium Pharmaceutical	3.4356 of 5 stars	$35.98 -1.7%	$57.50 +59.8%	+21.9%	$1.19B	$780.57M	17.64	210	Positive News
CRVS Corvus Pharmaceuticals	2.152 of 5 stars	$14.48 +7.3%	$33.33 +130.2%	+287.0%	$1.13B	N/A	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKBA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akebia Therapeutics (AKBA) Competitors

AKBA vs. SVRA, CALT, COLL, CRVS, and CGEM

How does Akebia Therapeutics compare to Savara?

Summary

How does Akebia Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Akebia Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Akebia Therapeutics compare to Corvus Pharmaceuticals?

Summary

How does Akebia Therapeutics compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akebia Therapeutics (AKBA) Competitors

AKBA vs. SVRA, CALT, COLL, CRVS, and CGEM

How does Akebia Therapeutics compare to Savara?

Is SVRA or AKBA more profitable?

Do insiders & institutionals hold more shares of SVRA or AKBA?

Do analysts prefer SVRA or AKBA?

Does the media favor SVRA or AKBA?

Which has stronger earnings & valuation, SVRA or AKBA?

Which has more risk and volatility, SVRA or AKBA?

Summary

How does Akebia Therapeutics compare to Calliditas Therapeutics AB (publ)?

Does the media prefer AKBA or CALT?

Which has stronger earnings and valuation, AKBA or CALT?

Which has more volatility & risk, AKBA or CALT?

Is AKBA or CALT more profitable?

Do analysts prefer AKBA or CALT?

Do insiders & institutionals have more ownership in AKBA or CALT?

Summary

How does Akebia Therapeutics compare to Collegium Pharmaceutical?

Which has more volatility & risk, COLL or AKBA?

Which has preferable valuation and earnings, COLL or AKBA?

Does the media prefer COLL or AKBA?

Do insiders & institutionals believe in COLL or AKBA?

Is COLL or AKBA more profitable?

Do analysts rate COLL or AKBA?

Summary

How does Akebia Therapeutics compare to Corvus Pharmaceuticals?

Do institutionals & insiders believe in CRVS or AKBA?

Do analysts rate CRVS or AKBA?

Is CRVS or AKBA more profitable?

Which has better valuation & earnings, CRVS or AKBA?

Which has more volatility and risk, CRVS or AKBA?

Does the media favor CRVS or AKBA?

Summary

How does Akebia Therapeutics compare to Cullinan Therapeutics?

Which has better earnings and valuation, CGEM or AKBA?

Which has more risk & volatility, CGEM or AKBA?

Do insiders and institutionals have more ownership in CGEM or AKBA?

Is CGEM or AKBA more profitable?

Does the media favor CGEM or AKBA?

Do analysts prefer CGEM or AKBA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools